• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Accenture, Orexo Team to Offer Digital Therapeutics through INTIENT™ Platform

Share:

November 19, 2020

Accenture (NYSE: ACN) has helped the U.S. subsidiary of Swedish pharmaceutical company Orexo launch its first digital therapeutic, vorvida®, for patients in the United States dealing with problematic alcohol use. vorvida® is a web-based digital platform that uses the INTIENT™ Patient solution suite, which is powered by Google Cloud, to enable secure patient interactions and connectivity to an ecosystem of third-party health care services.

A critical aspect to providing this population with a new treatment option was creating a digital solution that could immediately connect patients with health care services and scale to support the portfolio of Orexo’s future digital therapies, such as the ones for depression and opioid abuse.

“We are delighted to work with Accenture to make our digital therapies even more accessible to those who need them,” said Dennis Urbaniak, executive vice president, Digital Therapeutics, Orexo. “We know that many of our patients are concerned with confidentiality and privacy, and the INTIENT™ Platform provides a safe, secure platform through which individuals struggling with mental or behavioral issues can confidently get the care they need – right at their fingertips.”

Digital therapeutics are clinically validated patient treatments that provide access to novel care models and deliver health outcomes using a combination of digital inputs, artificial intelligence algorithms, and interventions to impact patients’ healthy behaviors. Orexo’s digital therapeutics are designed to learn from interactions and personalize the delivery of content to fit the unique needs of the individual. In addition to vorvida®, Orexo also offers deprexis® for the treatment of depression and anxiety, and modia™ for the treatment of opioid use disorder, which is expected to be available in the U.S. by the end of the year.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Orexo is a great example of how INTIENT™ is supporting the future of the life science industry, driven by a focus on New Science, by providing a secure digital solution for patient data and connectivity to the market of digital health innovations and services,” said Tony Romito, managing director, Global Patient Service, Accenture.

The INTIENT Patient solution suite is part of Accenture’s INTIENT™ platform, which supports the life science industry by providing cloud-based solutions for industry needs across R&D and Commercial.

Source: Prnews Wire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Global Pharma and Biotech CRM Software Market Report 2022: Extensive Capacity of Digital Health Applications and Their Potential in the Healthcare Industry is Attracting Investment and Fueling GrowthGlobal Pharma and Biotech CRM Software Market Report 2022: Extensive Capacity of Digital Health Applications and Their Potential in the Healthcare Industry is Attracting Investment and Fueling Growth
  • Pfizer Completes Acquisition of Trillium TherapeuticsPfizer Completes Acquisition of Trillium Therapeutics
  • Study Finds Twitter Mentions of Pneumonia up in Europe Ahead of COVID-19 OutbreakStudy Finds Twitter Mentions of Pneumonia up in Europe Ahead of COVID-19 Outbreak
  • SOHM Announces Its Acquisition of ABBIE, a World-Class Gene-Editing Platform Which Can Deliver Genetic Payloads Using Non-Viral VectorsSOHM Announces Its Acquisition of ABBIE, a World-Class Gene-Editing Platform Which Can Deliver Genetic Payloads Using Non-Viral Vectors
  • Verizon expands support of Veterans with unlimited access to U.S. Department of Veterans Affairs video telehealth serviceVerizon expands support of Veterans with unlimited access to U.S. Department of Veterans Affairs video telehealth service
  • Japanese Startup AI Medical Secures FDA Approval for Real-Time Endoscopic AI PlatformJapanese Startup AI Medical Secures FDA Approval for Real-Time Endoscopic AI Platform
  • OM Surgical Solutions Acquires Docs Dial LLCOM Surgical Solutions Acquires Docs Dial LLC
  • PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION BiotechPerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications